Actinium Pharmaceuticals Inc (ATNM)
8.74
+0.96
(+12.34%)
USD |
NYAM |
May 02, 16:00
8.74
0.00 (0.00%)
After-Hours: 17:24
Actinium Pharmaceuticals Cash from Financing (Quarterly): 14.77M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 14.77M |
| December 31, 2023 | 1.192M |
| September 30, 2023 | 2.86M |
| June 30, 2023 | 10.05M |
| March 31, 2023 | 0.77M |
| December 31, 2022 | 4.893M |
| September 30, 2022 | 1.575M |
| June 30, 2022 | 16.66M |
| March 31, 2022 | -0.022M |
| December 31, 2021 | 0.801M |
| September 30, 2021 | 5.776M |
| June 30, 2021 | 14.30M |
| March 31, 2021 | 14.34M |
| December 31, 2020 | 21.83M |
| September 30, 2020 | -0.23M |
| June 30, 2020 | 52.04M |
| March 31, 2020 | 2.542M |
| December 31, 2019 | -0.044M |
| September 30, 2019 | 0.35M |
| June 30, 2019 | 15.02M |
| March 31, 2019 | 1.792M |
| December 31, 2018 | 3.166M |
| September 30, 2018 | 0.0039M |
| June 30, 2018 | -1.058M |
| March 31, 2018 | 14.87M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.0275M |
| September 30, 2017 | 14.96M |
| June 30, 2017 | 1.908M |
| March 31, 2017 | 1.917M |
| December 31, 2016 | 9.25M |
| September 30, 2016 | 0.6435M |
| June 30, 2016 | 4.484M |
| March 31, 2016 | 1.398M |
| December 31, 2015 | 4.866M |
| September 30, 2015 | 2.335M |
| June 30, 2015 | 11.94M |
| March 31, 2015 | 18.39M |
| December 31, 2014 | 0.039M |
| September 30, 2014 | 1.342M |
| June 30, 2014 | 11.49M |
| March 31, 2014 | 2.837M |
| December 31, 2013 | 2.896M |
| September 30, 2013 | -0.0332M |
| June 30, 2013 | 3.426M |
| March 31, 2013 | -0.0653M |
| December 31, 2012 | 4.470M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | -0.00 |
| March 31, 2012 | 0.6602M |
| December 31, 2011 | 6.005M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.23M
Minimum
Sep 2020
52.04M
Maximum
Jun 2020
8.973M
Average
3.876M
Median
Cash from Financing (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 0.352M |
| Eli Lilly and Co | -311.30M |
| Cellectar Biosciences Inc | 0.441M |
| Outlook Therapeutics Inc | -0.0032M |
| Bristol-Myers Squibb Co | 14.64B |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.374M |
| Cash from Investing (Quarterly) | -0.011M |
| Free Cash Flow | -39.72M |
| Free Cash Flow Per Share (Quarterly) | -0.2648 |
| Free Cash Flow Yield | -16.74% |